In the neoadjuvant setting, patients with stage 1, node-negative HER2 + BC were treated with zanidatamab in a chemotherapy-free regimen, with preliminary data showing 36% of patients achieving pCR and 64% of patient achieving pCR or RCB-1 [139]. Here, ERBB2 is linked to breast cancer.